Synlogic, Inc.

Synlogic, Inc.

Synlogic, Inc.

Overview
Date Founded

2017

Headquarters

301 Binney Street,Suite 402,Cambridge, MA 02142

Type of Company

Public

Employees (Worldwide)

74

Industries

Biotechnology

Company Description

Synlogic, Inc. is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Executives & Employees

Co-Founder

Co-Founder

President & Chief Executive Officer

Chief Financial & Accounting Officer

Secretary & General Counsel

Chief Scientific Officer

Chief Human Resources Officer

Head of Translational Sciences & Product Development

Head of Technical Operations

Senior Vice President, Process Development & Manufacturing

Board of Directors

Partner Legacy Funds at Atlas Venture, Inc.

President & Chief Executive Officer at bluebird bio, Inc.

Chief Financial Officer, Treasurer & Principal Accounting Officer at Syndax Pharmaceuticals, Inc.

President & Chief Executive Officer at Synlogic, Inc.

Partner at OrbiMed Advisors LLC

Partner at NEA Management Co. LLC

General Partner at Sofinnova Ventures, Inc.

Future Chief Executive Officer at Lyndra Therapeutics, Inc. (Effective 09/2019)

Paths to Synlogic, Inc.
Potential Connections via
Relationship Science
You
Synlogic, Inc.
Owners & Shareholders
Details Hidden

Aquilo Capital Management focuses on long/short investments in the stocks of companies in the life sciences and biotechnology sectors

Details Hidden

Deerfield Management Co. focuses on investments in growth stocks across the healthcare sector. They target companies with sound fundamentals, long-term earnings growth potential and the potential to capitalize on market trends. Deerfield's approach is based on extensive fundamental research into healthcare sector assets and investment opportunities. They invest mainly in US companies or companies that issue securities available in US public markets. Although this is their focus, there is no geographic limitation on investments and Deerfield may invest outside the US when situations warrant. Their funds generally pursue one of 3 strategies: Large-Cap, Special Situations and Private Design.Deerfield's Large-Cap strategy invests mainly in debt and equity securities, including exchange traded derivative securities, of publicly-traded companies in the healthcare sector. The strategy seeks capital appreciation through a combination of security selection based on fundamental analysis, diversification through investments in stock, debt and derivatives and a mix of long and short positions.The firm's Special Situations strategy emphasizes investments in publicly traded healthcare companies with smaller market-caps. At least 90% of investments must in healthcare companies, and essentially all investments are healthcare related. Investments include equity, debt, royalties or other assets, some of which may have limited liquidity. The strategy makes both long and short investments and may utilize leverage.Deerfield's Private Design strategy invests in public and private healthcare companies using privately created instruments, structures and transactions. This may include, but is not limited to, joint ventures, project financing, contracting for revenue streams, purchasing products/services outright (including intellectual property), participating in LBOs, restructurings and outright buyouts, and developing/participating in the development and sale of therapeutics, medical devices and healthcare products/services.

Recent Transactions
Details Hidden

Synlogic, Inc. issued Common Stock

Transaction Advisors
Escrow Agent

Advised onSynlogic, Inc. issued Common Stock

Underwriter

Advised onSynlogic, Inc. issued Common Stock

Legal Advisor

Advised onSynlogic, Inc. issued Common Stock

Professional

Advised onSynlogic, Inc. issued Common Stock

Professional

Advised onSynlogic, Inc. issued Common Stock

Legal Advisor

Advised onSynlogic, Inc. issued Common Stock

Advisors & Consultants
Advisor

Founder at Synlogic, Inc.

Advisor

Advisor at Atlas Venture, Inc.

Advisor

Director & Chief Scientist at Kalion, Inc.

Clients

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Cronos Group, Inc. engages in the production and sale of cannabis in federally legal jurisdictions, including Canada and Germany. Its portfolio includes Peace Naturals, Original BC (OGBC) and Whistler Medical Marijuana Company (WMMC). The company was founded by Lorne Michael Gertner and Paul Rosen on August 21, 2012 and is headquartered in Toronto, Canada.

Key Stats and Financials As of 2018
Market Capitalization
$204M
Total Enterprise Value
$45.2M
Earnings Per Share
$-2.03
Revenue
$2.52M
Net Profit
$-48.4M
EBITDA
$-48.8M
EBITDAMargin
-1,936.87%
Total Debt
$476K
Total Equity
$124M
Enterprise Value Sales
17.92x
TEVNet Income
-0.93x
Debt TEV
0.01x
Suppliers
Rosetta Genomics Ltd. Medical Products & Equipment | REHOVOT , TA

Rosetta Genomics Ltd. provides therapeutic, diagnostic product development and medical research services. The company develops and commercializes new diagnostic tests based on various genomics markers, including DNA, microRNA and protein biomarkers and using various technologies, including, qPCR, microarrays, next generation sequencing and fluorescence in situ hybridization. It offers proprietary microRNA technologies such as Rosetta Cancer Origin, mi-KIDNEY, and RosettaGX Reveal Test. The company was founded by Isaac Bentwich on March 9, 2000 and is headquartered in Rehovot, Israel.

Boston University Trusts & Funds | Boston, MA

Boston University (most commonly referred to as BU) is a private research university located in Boston, Massachusetts. The university is nonsectarian, but is historically affiliated with the United Methodist Church. The university has more than 4,000 faculty members and 29,000 students,and is one of Boston's largest employers. It offers bachelor's degrees, master's degrees, and doctoral degrees, and medical and dental degrees through 18 schools and colleges on two urban campuses. The main campus is situated along the Charles River in Boston's Fenway-Kenmore and Allston neighborhoods, while the Boston University Medical Campus is in Boston's South End neighborhood. BU also operates 75 study abroad programs in over 33 cities in over 20 countries and has internship opportunities in 10 different countries (including the United States and abroad).

Massachusetts Institute of Technology Computer Software | CAMBRIDGE, MA

Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts, United States. MIT has five schools and one college, containing a total of 32 academic departments, with a strong emphasis on scientific, engineering, and technological education and research. Founded in 1861 in response to the increasing industrialization of the United States, the institute used a polytechnic university model and stressed laboratory instruction. MIT was elected to the Association of American Universities in 1934.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Bausch Health Cos., Inc. Pharmaceuticals - Laval, QC

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Celgene Corp. Pharmaceuticals

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Synlogic, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Synlogic, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Synlogic, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/synlogic-inc-230679201
  • https://relationshipscience.com/organization/synlogic-inc-230679201